Jones G

ArticleKetamine

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Hejazi N, Kheirkhah M, Riedner B +6

PreprintMescaline

Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline

Tabaac BJ, Shinozuka K, Fadel +3

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine.

Courtes AC, Myers B, Daly N +4

Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health.

Ehmann S, Hager NM, Regier PS +2

PreprintPsilocybin

Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers

Johnston J, Jones G, Peng S +12

PreprintMDMA

Assessing the suitability of ‘mass loss analysis’ as a low cost, low technology test to approximate MDMA content in ecstasy tablets, using laboratory and field comparisons

Pascoe M, Jones G, Simmons H +5

PreprintPsilocybin

Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey

Ehmann S, Hager NM, Regier PS +2

ArticlePsychedelics

Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use.

Herrmann FM, Jones G, Low DM +3

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.

Jones G

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.

Jones G, Lowe MX, Nayak S +5

ArticlePsychedelics

The Relationship Between Changes in Mindfulness and Subsequent Changes in Well-Being Following Psychedelic Use: Prospective Cohort Study.

Jones G, Herrmann F, Bear A +2

Europe PMC2024

ArticleKetamine

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.

Vecera CM, C Courtes A, Jones G +2

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.

Jones G, Al-Suwaidi M, Castro-Ramirez F +3

Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.

Jones G, Herrmann F, Wang E

ArticleMDMA

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.

Jones G, Lipson J, Wang E

ArticleMDMA

Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.

Jones G, Arias D, Nock M

ArticleMDMA

Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder.

Okano L, Jones G, Deyo B +2

Associations between classic psychedelics and nicotine dependence in a nationally representative sample.

Jones G, Lipson J, Nock MK

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.

Jones G, Ricard JA, Lipson J +1